These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20874252)

  • 1. Regulatory effects of interferon-β on osteopontin and interleukin-17 expression in multiple sclerosis.
    Hong J; Hutton GJ
    J Interferon Cytokine Res; 2010 Oct; 30(10):751-7. PubMed ID: 20874252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS.
    Chen M; Chen G; Nie H; Zhang X; Niu X; Zang YC; Skinner SM; Zhang JZ; Killian JM; Hong J
    Eur J Immunol; 2009 Sep; 39(9):2525-36. PubMed ID: 19670379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential gene expression and translational approaches to identify biomarkers of interferon beta activity in multiple sclerosis.
    Croze E
    J Interferon Cytokine Res; 2010 Oct; 30(10):743-9. PubMed ID: 20874251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis.
    Murugaiyan G; Mittal A; Weiner HL
    J Immunol; 2008 Dec; 181(11):7480-8. PubMed ID: 19017937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of short-term interferon-β treatment on cytokines in multiple sclerosis: significant modulation of IL-17 and IL-23.
    Kürtüncü M; Tüzün E; Türkoğlu R; Petek-Balcı B; Içöz S; Pehlivan M; Birişik Ö; Ulusoy C; Shugaiv E; Akman-Demir G; Eraksoy M
    Cytokine; 2012 Aug; 59(2):400-2. PubMed ID: 22652415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFN-beta inhibits human Th17 cell differentiation.
    Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
    J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis.
    van Beers MM; Jiskoot W; Schellekens H
    J Interferon Cytokine Res; 2010 Oct; 30(10):767-75. PubMed ID: 20874254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
    Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
    Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shifting therapeutic attention in MS to osteopontin, type 1 and type 2 IFN.
    Steinman L
    Eur J Immunol; 2009 Sep; 39(9):2358-60. PubMed ID: 19681057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical review: assessment of interferon-β immunogenicity in multiple sclerosis.
    Bendtzen K
    J Interferon Cytokine Res; 2010 Oct; 30(10):759-66. PubMed ID: 20874253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Cobalamin on Interleukin 10, Osteopontin, and Related MicroRNAs in Multiple Sclerosis.
    Hesamian MS; Shaygannejad V; Golabi M; Mirmosayyeb O; Andalib A; Eskandari N
    Iran J Allergy Asthma Immunol; 2022 Jun; 21(3):332-343. PubMed ID: 35822683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiles reveal homeostatic dynamics during interferon-beta therapy in multiple sclerosis.
    Annibali V; Di Giovanni S; Cannoni S; Giugni E; Bomprezzi R; Mattei C; Elkahloun A; Coccia EM; Alfò M; Orzi F; Ristori G; Salvetti M
    Autoimmunity; 2007 Feb; 40(1):16-22. PubMed ID: 17364493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFN-β and multiple sclerosis: cross-talking of immune cells and integration of immunoregulatory networks.
    Severa M; Rizzo F; Giacomini E; Salvetti M; Coccia EM
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):229-39. PubMed ID: 25498525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of interferon-beta on interleukin-10 in multiple sclerosis patients.
    Ersoy E; Kuş CN; Sener U; Coker I; Zorlu Y
    Eur J Neurol; 2005 Mar; 12(3):208-11. PubMed ID: 15693810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interferon -beta therapy in multiple sclerosis].
    Satoh J
    Nihon Rinsho; 2006 Jul; 64(7):1297-309. PubMed ID: 16838648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
    Link J
    Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease.
    Chabas D; Baranzini SE; Mitchell D; Bernard CC; Rittling SR; Denhardt DT; Sobel RA; Lock C; Karpuj M; Pedotti R; Heller R; Oksenberg JR; Steinman L
    Science; 2001 Nov; 294(5547):1731-5. PubMed ID: 11721059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon-regulated chemokine/cytokine responses within the central nervous system.
    Shapiro AM; Jack CS; Lapierre Y; Arbour N; Bar-Or A; Antel JP
    Arch Neurol; 2006 Sep; 63(9):1296-9. PubMed ID: 16966508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.